KR20060023111A - 피하 전달 시스템, 상기 시스템 제조공정 및 콜린 효능성결핍 장애 치료를 위한 상기 시스템의 이용 - Google Patents

피하 전달 시스템, 상기 시스템 제조공정 및 콜린 효능성결핍 장애 치료를 위한 상기 시스템의 이용 Download PDF

Info

Publication number
KR20060023111A
KR20060023111A KR1020057016999A KR20057016999A KR20060023111A KR 20060023111 A KR20060023111 A KR 20060023111A KR 1020057016999 A KR1020057016999 A KR 1020057016999A KR 20057016999 A KR20057016999 A KR 20057016999A KR 20060023111 A KR20060023111 A KR 20060023111A
Authority
KR
South Korea
Prior art keywords
group
formula
delivery system
poly
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057016999A
Other languages
English (en)
Korean (ko)
Inventor
삐에르또 스깔파로
Original Assignee
데비오 레쉑쉐 빠르마슈띠끄 에스.아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데비오 레쉑쉐 빠르마슈띠끄 에스.아 filed Critical 데비오 레쉑쉐 빠르마슈띠끄 에스.아
Publication of KR20060023111A publication Critical patent/KR20060023111A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
KR1020057016999A 2003-03-14 2004-03-15 피하 전달 시스템, 상기 시스템 제조공정 및 콜린 효능성결핍 장애 치료를 위한 상기 시스템의 이용 Ceased KR20060023111A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IB0300942 2003-03-14
IBPCT/IB03/00942 2003-03-14
IB0304945 2003-11-05
IBPCT/IB03/04945 2003-11-05

Publications (1)

Publication Number Publication Date
KR20060023111A true KR20060023111A (ko) 2006-03-13

Family

ID=32992641

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057016999A Ceased KR20060023111A (ko) 2003-03-14 2004-03-15 피하 전달 시스템, 상기 시스템 제조공정 및 콜린 효능성결핍 장애 치료를 위한 상기 시스템의 이용

Country Status (23)

Country Link
US (1) US20070059369A1 (cg-RX-API-DMAC7.html)
EP (2) EP1603532B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006520378A (cg-RX-API-DMAC7.html)
KR (1) KR20060023111A (cg-RX-API-DMAC7.html)
AT (1) ATE404170T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004218896B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0407818A (cg-RX-API-DMAC7.html)
CA (1) CA2518883A1 (cg-RX-API-DMAC7.html)
CY (1) CY1108482T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004015744D1 (cg-RX-API-DMAC7.html)
DK (1) DK1603532T3 (cg-RX-API-DMAC7.html)
EA (1) EA011169B1 (cg-RX-API-DMAC7.html)
ES (1) ES2312981T3 (cg-RX-API-DMAC7.html)
IL (1) IL170759A (cg-RX-API-DMAC7.html)
IS (1) IS8067A (cg-RX-API-DMAC7.html)
MX (1) MXPA05009626A (cg-RX-API-DMAC7.html)
NO (1) NO20054258L (cg-RX-API-DMAC7.html)
NZ (1) NZ542459A (cg-RX-API-DMAC7.html)
PL (1) PL1603532T3 (cg-RX-API-DMAC7.html)
PT (1) PT1603532E (cg-RX-API-DMAC7.html)
SI (1) SI1603532T1 (cg-RX-API-DMAC7.html)
UA (1) UA82226C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004080436A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2432556T3 (es) 2004-08-04 2013-12-04 Evonik Corporation Métodos para fabricar dispositivos de suministro y sus dispositivos
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US8956636B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
WO2011132157A1 (en) 2010-04-22 2011-10-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Oral sustained release formulation of huperzine a
WO2013173096A2 (en) * 2012-05-18 2013-11-21 Insero Health Inc. Conjugates of huperzine and analogs thereof
KR101811797B1 (ko) * 2013-04-03 2017-12-22 동국제약 주식회사 도네페질을 포함하는 비경구투여용 약제학적 조성물
JP7111375B2 (ja) * 2017-10-19 2022-08-02 株式会社佐藤園 学習記憶能力増強組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106979A (en) * 1989-02-21 1992-04-21 University Of Pittsburgh Method for the synthesis of huperzine A and analogs thereof and compounds useful therein
CN1125725A (zh) * 1994-12-28 1996-07-03 中国科学院上海药物研究所 一类海克林碱衍生物及它的用途
FR2756493B1 (fr) * 1996-12-02 2001-04-13 Delab Dispositif d'administration locale de formulations solides ou semi-solides
US6352715B1 (en) 1998-02-19 2002-03-05 Sagittarius Life Science Corp Transdermal rate-controlled delivery of Huperzine A for treatment of alzheimer's disease
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
CN1279065A (zh) 1999-07-06 2001-01-10 青岛科达生物工程有限公司 一种治疗记忆障碍和老年痴呆的药物组合物
CN1194688C (zh) * 2001-07-03 2005-03-30 山东绿叶制药股份有限公司 石杉碱甲及其衍生物或其盐的注射用缓释微球及其制备方法
CN1383824A (zh) 2002-05-21 2002-12-11 浙江省医学科学院 石杉碱鼻腔给药制剂

Also Published As

Publication number Publication date
IL170759A (en) 2010-06-16
EA011169B1 (ru) 2009-02-27
EP1977735A1 (en) 2008-10-08
EP1603532A1 (en) 2005-12-14
DK1603532T3 (da) 2008-12-08
AU2004218896A1 (en) 2004-09-23
HK1089085A1 (zh) 2006-11-24
ES2312981T3 (es) 2009-03-01
NZ542459A (en) 2008-12-24
AU2004218896B2 (en) 2010-04-01
SI1603532T1 (sl) 2009-02-28
DE602004015744D1 (de) 2008-09-25
IS8067A (is) 2005-10-11
CA2518883A1 (en) 2004-09-23
US20070059369A1 (en) 2007-03-15
EA200501433A1 (ru) 2006-02-24
PL1603532T3 (pl) 2009-02-27
CY1108482T1 (el) 2014-04-09
NO20054258D0 (no) 2005-09-15
WO2004080436A1 (en) 2004-09-23
MXPA05009626A (es) 2005-10-18
NO20054258L (no) 2005-11-24
EP1603532B1 (en) 2008-08-13
PT1603532E (pt) 2008-11-20
ATE404170T1 (de) 2008-08-15
JP2006520378A (ja) 2006-09-07
BRPI0407818A (pt) 2006-02-14
UA82226C2 (uk) 2008-03-25

Similar Documents

Publication Publication Date Title
TWI255186B (en) Sustained-release analgesic compounds
US8153149B2 (en) Controlled delivery system
US8475823B2 (en) Baclofen formulation in a polyorthoester carrier
EP2910242B1 (en) Durable analgetic sebacoyl dinalbuphine ester-plga controlled release formulation
US6277393B1 (en) Systemic and/or local (topical) application of tetracycline and/or tetracycline derivative(s) for treating, suppressing and preventing of cerebrovascular diseases, traumas and damages of nervous system
KR20020016832A (ko) 모르핀 글루코네이트로 이루어진 조성물 및 방법
JP2011520801A (ja) 皮膚病変を治療するためのオピオイド組成物
DE794794T1 (de) Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
CA2781436A1 (en) Arachidonic acid analogs and methods for analgesic treatment using same
WO2000025821A1 (en) Method of treating and diagnosing restless legs syndrome and corresponding means
EP1603532B1 (en) Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders
AU2012201226B2 (en) Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
RU2476209C1 (ru) Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
CN100398093C (zh) 皮下给药系统、其制备方法及其治疗胆碱能缺乏障碍的用途
HK1089085B (en) Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders
AU2016200966A1 (en) Sustained local anesthetic composition containing preferably a sugar ester such as SAIB

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050912

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090217

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110217

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110831

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110217

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I